Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Presentations
Date Title
Jun 13, 2017
Jan 6, 2017
Archived Events
Date Event Details
Jul 11, 2017
8:00 AM ET
Key Opinion Leader Meeting: Immuno-Oncology Combinations Discussion with Jeffrey Weber, MD, PhD and Matthew Hellmann, MD

The meeting will feature presentations by key opinion leaders Jeffrey Weber, MD, PhD (NYU, Perlmutter Cancer Center) and Matthew Hellmann, MD (Memorial Sloan Kettering Cancer Center) who will discuss the present and future landscape of immuno-oncology combinations in solid tumors, including recent advances presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. There will be a Q&A session immediately following the presentations. 

Mirati Therapeutics' management team will also provide an overview of the Company’s product pipeline, including their clinical-stage immuno-oncology programs that combine checkpoint inhibitors with their novel kinase inhibitor, sitravatinib, and their spectrum selective HDAC inhibitor, mocetinostat. 

Jun 7, 2017
3:30 PM ET
2017 Jefferies Global Healthcare Conference
Speaker: Chris LeMasters, Chief Business Officer
Feb 16, 2017
2:30 AM ET
Leerink Partners 6th Annual Global Healthcare Conference
Speaker: Charles M. Baum , M.D, Ph.D., President and CEO
= add file to Briefcase

ABSTRACTS AND POSTERS

Date Event Details
Dec 6, 2016
IASLC 2016 TiP Poster #5384
Dec 6, 2016
IASLC 2016 TiP Poster #4795
Dec 6, 2016
IASLC 2016 TiP Poster #4109
Dec 6, 2016
IASLC 2016 TiP Poster #5521
Oct 8, 2016
ESMO 2016 TiP Poster #1293
Jun 5, 2016
A First-in-Human Phase 1 Study of Receptor Tyrosine Kinase (RTK) Inhibitor anced Solid Tumors
Jun 4, 2016
Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors
Jun 4, 2016
Phase 2, Parallel-Arm Study of Receptor Tyrosine Kinase(RTK) Inhibitor MGCD265 in Patients (pts) with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor (MET)
Apr 19, 2016
The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations
AACR 2016
Apr 18, 2016
Evaluation of the mechanism of MET-dependent cellular transformation and potent cytoreductive activity of MGCD265 in novel MET exon 14 mutation positive cancer models
AACR 2016
Apr 16, 2016
AACR 2016 Poster #4021
Sep 27, 2015
A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tumors
2015 European Cancer Congress
Sep 9, 2015
Evaluation of the MET/Axl Receptor Tyrosine Kinase (RTK) Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Axl Amplification
World Conference on Lung Cancer 2015
Sep 8, 2015
In Vitro and In Vivo Evaluation of the Kinase Inhibitor, MGCD516, in TRK and RET Fusion Cancer cells
World Conference on Lung Cancer 2015
May 30, 2015
Phase 1 Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD265, in Patients (pts) with Advanced Solid Tumors
ASCO 2015
May 30, 2015
A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor MGCD516 in Patients with Advanced Solid Tumors
ASCO 2015
May 29, 2015
A Phase 2 Study of the Histone Deacetylase (HDAC) Inhibitor Mocetinostat in Patients with Urothelial Carcinoma (UC) and Inactivating Alterations of Acetyltransferase Genes
ASCO 2015